Specifically, we measured levels of six phosphorylated and six nonphosphorylated tau peptides in plasma samples from two independent cohorts of sporadic AD: the Swedish BioFINDER-2 study (n = 549) and Translational Biomarkers in Aging and Dementia (TRIAD) cohort (n = 140). This evidence concerns the gene MAPT and Alzheimer disease.